FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:1195-1197 March 13, 2008 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Jonker, D. J. PubMed Citation

To the Editor: The study by Jonker et al. (Nov. 15 issue)¹ showed that cetuximab improved survival among patients with colorectal cancer, but the authors give no details regarding sites of metastases in the cetuximab group. Were metastatic sites in patients receiving cetuximab correlated with survival? The authors do not mention thromboembolism, which may be associated with poor survival among patients with cancer.² Was cetuximab associated with an increased risk of thromboembolism?

Feng Yang, M.D.
Deliang Fu, M.D.
Quanxing Ni, M.D.
Huashan Hospital
Shanghai 200040, China
surgeonfu@yahoo.com.cn

1. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-2048. [Free Full Text]
2. Mandalà M, Moro C, Labianca R, Ferretti G. Erlotinib in pancreatic cancer patients: do we need more information from the NCIC CTG trial? J Clin Oncol 2007;25:4320-4321. [Free Full Text]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.